Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2023 Feb 1;118(2):284-293.
doi: 10.14309/ajg.0000000000002008. Epub 2022 Aug 22.

Systematic Review and Meta-Analysis on the Effects of Lactulose and Rifaximin on Patient-Reported Outcomes in Hepatic Encephalopathy

Andrew M Moon  1 , Hannah P Kim  2 , Yue Jiang  3 , Gabriel Lupu  4 , Jennifer S Bissram  5 , A Sidney Barritt 4th  1 , Elliot B Tapper  6   7
Affiliations
Meta-Analysis

Systematic Review and Meta-Analysis on the Effects of Lactulose and Rifaximin on Patient-Reported Outcomes in Hepatic Encephalopathy

Andrew M Moon et al. Am J Gastroenterol. .

Abstract

Introduction: Patients with hepatic encephalopathy (HE) suffer from significant symptoms and impaired quality of life. Improved understanding on the potential benefits of first-line HE therapies may aid patient-provider discussions regarding expected benefits of HE treatments. We aimed to perform a systematic review to assess the effects of lactulose and rifaximin on patient-reported outcomes (PROs).

Methods: We searched MEDLINE, EMBASE, and Cochrane Library databases for randomized trials or prospective cohort studies using lactulose and/or rifaximin for the management of HE and assessing changes in PRO using PRO instruments. Physician reviewers independently reviewed titles, abstracts, and full texts and extracted data independently. We performed random-effects meta-analyses to examine the effects of lactulose and rifaximin on PROs.

Results: We identified 16 studies representing 1,376 patients that met inclusion criteria. Most studies assessed treatment of covert HE. In patients with covert HE, lactulose significantly improved overall patient-reported health-related quality of life measured by the Sickness Impact Profile with an estimated pooled mean difference of 6.92 (95% confidence interval: 6.66-7.18) and showed improvements in several subscales. Conversely, rifaximin demonstrated a nonstatistically significant mean difference in the total Sickness Impact Profile of 4.76 (95% confidence interval: -4.23 to 13.76), with strong evidence of heterogeneity between these studies. Studies examining other PRO instruments showed improvements in overall health-related quality of life, social functioning, and sleep from both lactulose and rifaximin.

Discussion: Patients with HE treated with lactulose or rifaximin reported improvements in important PROs. These results may inform provider-patient communication and help manage patient expectations regarding the potential benefits of HE therapies.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.. Proposed conceptual framework of HRQOL in hepatic encephalopathy
Figure 2.
Figure 2.. Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) diagram of studies included in systematic review
Figure 3.
Figure 3.. Pooled mean difference in total Sickness Index Profile (SIP) scores among patients treated with lactulose
Figure 4.
Figure 4.. Percentage change in patient reported outcomes among patients with HE treated with lactulose and/or rifaximin for
(A) overall health-related quality of life, (B) sleep, (C) physical activity, and (D) social activity Percentage change based on total range of scores for each individual patient reported outcome instrument. Adjacent bars come from same study and positive values denote improvement in patient-reported outcomes. SIP: Sickness Index Profile; CLDQ: Chronic Liver Disease Questionnaire; CQoLQ: Modified Chinese QoL Questionnaire; ESS: Epworth Sleepiness Scale; PSQI: Pittsburgh Sleep Quality Index; WHOQOL-BREF: World Health Organization Quality of Life-BREF; SF-36: 36-Item Short Form Survey; SF-8: 8-Item Short Form Survey; * Intragroup difference (i.e. before vs after) significant at p<0.05; † Intergroup difference (i.e. treatment vs comparator) significant at p<0.05; ^ Short-term (8 weeks) lactulose; ‡ Long-term (24 weeks) lactulose; Statistical significance not reported for CLDQ (Sanyal et al.)
See this image and copyright information in PMC

References

    1. Ferenci P, Lockwood A, Mullen K, et al. Hepatic encephalopathy--definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998. Hepatology 2002;35:716–21. - PubMed
    1. Bajaj JS, Cordoba J, Mullen KD, et al. Review article: the design of clinical trials in hepatic encephalopathy--an International Society for Hepatic Encephalopathy and Nitrogen Metabolism (ISHEN) consensus statement. Aliment Pharmacol Ther 2011;33:739–47. - PMC - PubMed
    1. Vilstrup H, Amodio P, Bajaj J, et al. Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver. Hepatology 2014;60:715–35. - PubMed
    1. American Association for the Study of Liver D, European Association for the Study of the L. Hepatic encephalopathy in chronic liver disease: 2014 practice guideline by the European Association for the Study of the Liver and the American Association for the Study of Liver Diseases. J Hepatol 2014;61:642–59. - PubMed
    1. Kimer N, Krag A, Moller S, et al. Systematic review with meta-analysis: the effects of rifaximin in hepatic encephalopathy. Aliment Pharmacol Ther 2014;40:123–32. - PubMed

Publication types

MeSH terms